George Elston - 09 Feb 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2025
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 18:19:35 UTC
Previous filing
07 Jan 2025
Next filing
27 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +5,834 +8.4% $0.000000 75,550 09 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5,834 -100% $0.000000 0 09 Feb 2025 Common Stock 5,834 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,150 shares acquired on January 31, 2025 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.